Comparative Pharmacology
Head-to-head clinical analysis: LUMATEPERONE versus ZIPRASIDONE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMATEPERONE versus ZIPRASIDONE MESYLATE.
LUMATEPERONE vs ZIPRASIDONE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lumateperone is an atypical antipsychotic with a unique mechanism of action: it acts as a 5-HT2A receptor antagonist, a dopamine D2 receptor antagonist, and a serotonin reuptake inhibitor. It also modulates glutamate via enhanced AMPA and NMDA receptor activity.
Ziprasidone mesylate is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also antagonizes 5-HT1D, 5-HT2C, and alpha1-adrenergic receptors, and inhibits serotonin and norepinephrine reuptake.
42 mg orally once daily, taken with food and at least 240 mL of water, with a titration schedule: 42 mg daily for 7 days, then 21 mg twice daily thereafter.
20 mg intramuscularly (IM) as needed, not to exceed 40 mg/day; oral: 20 mg twice daily with food, titrated up to 80 mg twice daily. Maximum: 160 mg/day oral.
None Documented
None Documented
Terminal elimination half-life is approximately 13 hours in the plasma, supporting once-daily dosing. Steady state is reached within 5–7 days.
Terminal elimination half-life is approximately 2.2 hours (range 1.4–3.6 h) for the mesylate salt; clinical context: requires twice-daily dosing.
Approximately 80% of the dose is excreted in feces (as unchanged drug and metabolites) and about 11% in urine. Less than 1% is excreted as unchanged lumateperone in urine.
Approximately 20% renal, 80% fecal/biliary. Unchanged drug accounts for <1% of renal excretion.
Category C
Category A/B
Atypical Antipsychotic
Atypical Antipsychotic